Mobile Health, the nation's leading private-label Digital Health & Wellbeing platform, today announced the launch of a revolutionary engagement-based financial model for employers. This new approach ...

In a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with preservation of lean mass, outperforming the group given ...